Priority Review Sets Up Sanofi’s ‘Best In Disease’ Hemophilia Drug For 2023 Launch

Will Beat Gene Therapy To US Market

Sanofi can now expect an FDA decision in early 2023 on efanesoctocog, setting it up for a battle with Roche’s Hemlibra and BioMarin’s gene therapy Roctavian, which was just approved in the EU.

Sanofi logo
Sanofi looks to be on course to gain US approval by early 2023. • Source: Shutterstock

Momentum behind Sanofi’s novel hemophilia A drug efanesoctocog alfa is building, following the granting of a priority review of the blockbuster-in-waiting by the US regulator.

The Paris-headquartered major is calling its candidate’s efficacy “best in disease” and expects that, once approved, efanesoctocog will rival

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip